NASDAQ:COLL - Collegium Pharmaceutical Stock Price, Forecast & News

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical Inc (NASDAQ:COLL) released its quarterly earnings results on Wednesday, November, 6th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.03. The specialty pharmaceutical company earned $72.94 million during the quarter, compared to analyst estimates of $74.32 million. Collegium Pharmaceutical had a negative net margin of 3.86% and a negative return on equity of 13.14%. The business's revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.50) EPS. View Collegium Pharmaceutical's Earnings History.

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Collegium Pharmaceutical.

6 brokers have issued 12 month target prices for Collegium Pharmaceutical's stock. Their forecasts range from $22.00 to $36.00. On average, they anticipate Collegium Pharmaceutical's share price to reach $29.33 in the next year. This suggests a possible upside of 25.3% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

Media headlines about COLL stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Collegium Pharmaceutical earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Collegium Pharmaceutical.

Collegium Pharmaceutical saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,040,000 shares, an increase of 22.9% from the December 15th total of 1,660,000 shares. Based on an average daily trading volume, of 444,800 shares, the short-interest ratio is currently 4.6 days. Approximately 7.0% of the company's shares are sold short. View Collegium Pharmaceutical's Current Options Chain.

Some companies that are related to Collegium Pharmaceutical include Axsome Therapeutics (AXSM), Agios Pharmaceuticals (AGIO), Apellis Pharmaceuticals (APLS), Alkermes (ALKS), Biohaven Pharmaceutical (BHVN), Uniqure (QURE), Emergent Biosolutions (EBS), Genmab A/S (GMAB), Zai Lab (ZLAB), Amicus Therapeutics (FOLD), ChemoCentryx (CCXI), Karuna Therapeutics (KRTX), Zogenix (ZGNX), ArQule (ARQL) and Arena Pharmaceuticals (ARNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Celgene (CELG), Micron Technology (MU), Bausch Health Companies (BHC), Canopy Growth (CGC), GW Pharmaceuticals PLC- (GWPH) and Intercept Pharmaceuticals (ICPT).

(COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of COLL stock can currently be purchased for approximately $23.41.

Collegium Pharmaceutical has a market capitalization of $784.87 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.